2025 H2 -tulosraportti
157 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·32 min sittenDon't forget that a poor capital company is sitting on 1.8 million shares short. There's guaranteed to be a wild ketchup effect when they also have to cover. Remember also that all the flies want in on Thor and equity funds are loading up, so sit on your shares. This could be a new Algeta Biotek success in Norway. Thor can go up several hundred percent. Remember that Nel went completely crazy up from kr 1.14 to kr 32 and Nel lost several hundred million a year 🤠 Many I know became millionaires just by calmly sitting on the hydrogen hype. Doubling down on biotech like Thor is peanuts. New millionaires can be created here. Stay calm. Sit calmly and buy more is my advice.
6 min sittenhttps://www.novartis.com/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-care-across-metastatic-disease Pluvicto (Lu-177) is not a Thor product, but its approval strengthens the position of radioligand therapy as a whole and shifts RLT toward earlier stages of treatment. This drives increased investment, capacity, and interest in the alpha therapies in which Thor operates (Th-228 -Pb-212). It is no coincidence that as Lu-177 treatments expand, clinical programs involving Pb-212 are accelerating; the market is following a trajectory where beta therapy is established first, followed by a transition to more potent alpha therapies.
·3 t sittenhttps://www.heroya-industripark.no/en/news/2026/thor-medical-asa-alphaone-starts-commercial-production Does anyone know how many units are forecast in 2026-2027-2028?
Yes, the company has said that one can scale up. The question is probably not if, but rather when.
·4 t sitten · MuokattuAnyone have info on POC* on Friday?
- ·18 t sittenInvest tech's technical analysis: Automatic technical analysis. Medium term, 31. Jul 2026 Thor Medical ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock is moving in a rectangle formation between support at 3.92 kroner and resistance at 5.95 kroner. An established break of one of these levels will signal further direction. The stock has broken up through the resistance at approximately 5.50 kroner. Further upside is thus signaled, and there is now support at 5.50 kroner on reactions back. Volume has previously been high around price tops and low around price bottoms. The volume balance is also positive, which strengthens the trend picture. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated.
- ·18 t sittenRead about this and you will potentially understand what Thor could be worth. "The Norwegian biotechnology company Algeta was acquired by the German pharmaceutical giant Bayer in March 2014 for 17.6 billion kroner (2.1 billion euro). The acquisition followed a longer collaboration on the development and commercialization of the prostate cancer medicine Xofigo.Background and DetailsPrice: 336 kroner per share, corresponding to a total transaction value of approx. 17.6 billion kroner.Product: Xofigo (radium-223), a groundbreaking alpha-particle-based medicine against bone metastasis in prostate cancer.Founders: Founded in 1997 by chemist Roy H. Larsen and professor Øyvind S. Bruland.Consequences and Ripple EffectsDelisted: Algeta was delisted from Oslo Børs after the acquisition was formally completed in March 2014.Norwegian environment: Bayer maintained a significant presence in Norway, which has contributed to strengthening the Norwegian professional environment in radiopharmacy afterwards.Development: The sale is considered one of the biggest success stories in Norwegian biotechnology history, even though revenues for Xofigo later faced tougher competition and falling sales a decade later."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
157 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·32 min sittenDon't forget that a poor capital company is sitting on 1.8 million shares short. There's guaranteed to be a wild ketchup effect when they also have to cover. Remember also that all the flies want in on Thor and equity funds are loading up, so sit on your shares. This could be a new Algeta Biotek success in Norway. Thor can go up several hundred percent. Remember that Nel went completely crazy up from kr 1.14 to kr 32 and Nel lost several hundred million a year 🤠 Many I know became millionaires just by calmly sitting on the hydrogen hype. Doubling down on biotech like Thor is peanuts. New millionaires can be created here. Stay calm. Sit calmly and buy more is my advice.6 min sittenhttps://www.novartis.com/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-care-across-metastatic-disease Pluvicto (Lu-177) is not a Thor product, but its approval strengthens the position of radioligand therapy as a whole and shifts RLT toward earlier stages of treatment. This drives increased investment, capacity, and interest in the alpha therapies in which Thor operates (Th-228 -Pb-212). It is no coincidence that as Lu-177 treatments expand, clinical programs involving Pb-212 are accelerating; the market is following a trajectory where beta therapy is established first, followed by a transition to more potent alpha therapies.
- ·3 t sittenhttps://www.heroya-industripark.no/en/news/2026/thor-medical-asa-alphaone-starts-commercial-production Does anyone know how many units are forecast in 2026-2027-2028?Yes, the company has said that one can scale up. The question is probably not if, but rather when.
- ·4 t sitten · MuokattuAnyone have info on POC* on Friday?
- ·18 t sittenInvest tech's technical analysis: Automatic technical analysis. Medium term, 31. Jul 2026 Thor Medical ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock is moving in a rectangle formation between support at 3.92 kroner and resistance at 5.95 kroner. An established break of one of these levels will signal further direction. The stock has broken up through the resistance at approximately 5.50 kroner. Further upside is thus signaled, and there is now support at 5.50 kroner on reactions back. Volume has previously been high around price tops and low around price bottoms. The volume balance is also positive, which strengthens the trend picture. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated.
- ·18 t sittenRead about this and you will potentially understand what Thor could be worth. "The Norwegian biotechnology company Algeta was acquired by the German pharmaceutical giant Bayer in March 2014 for 17.6 billion kroner (2.1 billion euro). The acquisition followed a longer collaboration on the development and commercialization of the prostate cancer medicine Xofigo.Background and DetailsPrice: 336 kroner per share, corresponding to a total transaction value of approx. 17.6 billion kroner.Product: Xofigo (radium-223), a groundbreaking alpha-particle-based medicine against bone metastasis in prostate cancer.Founders: Founded in 1997 by chemist Roy H. Larsen and professor Øyvind S. Bruland.Consequences and Ripple EffectsDelisted: Algeta was delisted from Oslo Børs after the acquisition was formally completed in March 2014.Norwegian environment: Bayer maintained a significant presence in Norway, which has contributed to strengthening the Norwegian professional environment in radiopharmacy afterwards.Development: The sale is considered one of the biggest success stories in Norwegian biotechnology history, even though revenues for Xofigo later faced tougher competition and falling sales a decade later."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
157 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·32 min sittenDon't forget that a poor capital company is sitting on 1.8 million shares short. There's guaranteed to be a wild ketchup effect when they also have to cover. Remember also that all the flies want in on Thor and equity funds are loading up, so sit on your shares. This could be a new Algeta Biotek success in Norway. Thor can go up several hundred percent. Remember that Nel went completely crazy up from kr 1.14 to kr 32 and Nel lost several hundred million a year 🤠 Many I know became millionaires just by calmly sitting on the hydrogen hype. Doubling down on biotech like Thor is peanuts. New millionaires can be created here. Stay calm. Sit calmly and buy more is my advice.6 min sittenhttps://www.novartis.com/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-care-across-metastatic-disease Pluvicto (Lu-177) is not a Thor product, but its approval strengthens the position of radioligand therapy as a whole and shifts RLT toward earlier stages of treatment. This drives increased investment, capacity, and interest in the alpha therapies in which Thor operates (Th-228 -Pb-212). It is no coincidence that as Lu-177 treatments expand, clinical programs involving Pb-212 are accelerating; the market is following a trajectory where beta therapy is established first, followed by a transition to more potent alpha therapies.
- ·3 t sittenhttps://www.heroya-industripark.no/en/news/2026/thor-medical-asa-alphaone-starts-commercial-production Does anyone know how many units are forecast in 2026-2027-2028?Yes, the company has said that one can scale up. The question is probably not if, but rather when.
- ·4 t sitten · MuokattuAnyone have info on POC* on Friday?
- ·18 t sittenInvest tech's technical analysis: Automatic technical analysis. Medium term, 31. Jul 2026 Thor Medical ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock is moving in a rectangle formation between support at 3.92 kroner and resistance at 5.95 kroner. An established break of one of these levels will signal further direction. The stock has broken up through the resistance at approximately 5.50 kroner. Further upside is thus signaled, and there is now support at 5.50 kroner on reactions back. Volume has previously been high around price tops and low around price bottoms. The volume balance is also positive, which strengthens the trend picture. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated.
- ·18 t sittenRead about this and you will potentially understand what Thor could be worth. "The Norwegian biotechnology company Algeta was acquired by the German pharmaceutical giant Bayer in March 2014 for 17.6 billion kroner (2.1 billion euro). The acquisition followed a longer collaboration on the development and commercialization of the prostate cancer medicine Xofigo.Background and DetailsPrice: 336 kroner per share, corresponding to a total transaction value of approx. 17.6 billion kroner.Product: Xofigo (radium-223), a groundbreaking alpha-particle-based medicine against bone metastasis in prostate cancer.Founders: Founded in 1997 by chemist Roy H. Larsen and professor Øyvind S. Bruland.Consequences and Ripple EffectsDelisted: Algeta was delisted from Oslo Børs after the acquisition was formally completed in March 2014.Norwegian environment: Bayer maintained a significant presence in Norway, which has contributed to strengthening the Norwegian professional environment in radiopharmacy afterwards.Development: The sale is considered one of the biggest success stories in Norwegian biotechnology history, even though revenues for Xofigo later faced tougher competition and falling sales a decade later."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt